EL244
Based on 1 Customer Validation
EL244 is a dua Autotaxin (ATX) (IC50 = 50 nM) inhibitor and PPARγ (IC50 = 1.3 μM; Kd = 1.3 μM) agonist. EL244 demonstrates low cytotoxicity in human HepG2 cells (EC50 = 81.2 μM) with minimal inhibition of the cardiac hERG potassium channel (12% at 25 μM). EL244 significantly reduces pulmonary Lysophosphatidic Acid (LPA) levels, attenuates fibrosis, and restores respiratory function with limited systemic absorption in vivo. EL244 can be used for idiopathic pulmonary fibrosis and interstitial lung disease (ILD) research.
For research use only. We do not sell to patients.
- Purity : 99.55%
- CAS No.: 3047548-70-6
- Formula: C25H26Cl2N2O5S
- Molecular Weight:537.46
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
PPAR-γ 1.3 μM (IC50) |
Autotaxin 50 nM (IC50) |
Parmacokinetics
| Species | Dose | Route | Cmax |
|---|---|---|---|
| Mice[1] | 30 mg/kg | i.p. | 40 μM |
In Vivo
EL244 (15 mg/kg, inhaled administration, once daily for 15 days) post and before BLM administration has anti-fibrotic prophylactic effects in the BLM (oropharyngeal aspiration, 0.8 U/Kg)-induced model of pulmonary fibrosis in the BLM (oropharyngeal aspiration, 0.8 U/Kg)-induced mice model of pulmonary fibrosis[1].
EL244 (30 mg/kg, i.p., once) demonstrates favorable pharmacokinetics, achieving a plasma concentration of 40 μM within 1 hour, maintaining levels around 35 μM for up to 3 hours, and remaining detectable at approximately 15 μM even 9 hours post-dose, with its maximal pharmacodynamic effect coinciding at the 3-hour time point in the BLM (oropharyngeal aspiration, 0.8 U/Kg)-induced mice model of pulmonary fibrosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BLM (oropharyngeal aspiration, 0.8 U/Kg)-induced mice[1]
-
Dosage:15 mg/Kg
-
Administration:Inhaled administration, once daily for 7 days
-
Result:Diminished inflammation, Appeared fibrotic regions.
Restored all assessed respiratory functions and reduced vascular permeability.
Demonstrated strong anti-fibrotic effects, significantly reducing soluble collagen in BALF and Col1a1 expression in lung tissue.
Reduced collagen deposition and fewer and smaller fibrotic regions.
-
Animal Model:BLM (oropharyngeal aspiration, 0.8 U/Kg)-induced mice[1]
-
Dosage:15 mg/Kg
-
Administration:Inhaled administration, once daily for 15 days
-
Result:Improved respiratory functions.
Reduced BLM-induced pulmonary oedema and inflammation.
Reduced Soluble collagen levels in BALF and Col1a1 mrna expression in lung tissue.
Attenuated collagen deposition and the reduction of fibrotic regions.
Not caused any appreciable toxicity in the liver, as indicated by the ALT/AST levels.
Chemical Information
-
CAS No. 3047548-70-6
-
Appearance Solid
-
Molecular Weight 537.46
-
Formula C25H26Cl2N2O5S
-
Color White to off-white
-
SMILES
O=C1NC(C(S1)CC2=CC=C(C=C2)OCCC3CCN(CC3)C(OCC4=CC(Cl)=CC(Cl)=C4)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (186.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8606 mL | 9.3030 mL | 18.6060 mL | 46.5151 mL |
| 5 mM | 0.3721 mL | 1.8606 mL | 3.7212 mL | 9.3030 mL | |
| 10 mM | 0.1861 mL | 0.9303 mL | 1.8606 mL | 4.6515 mL | |
| 15 mM | 0.1240 mL | 0.6202 mL | 1.2404 mL | 3.1010 mL | |
| 20 mM | 0.0930 mL | 0.4652 mL | 0.9303 mL | 2.3258 mL | |
| 25 mM | 0.0744 mL | 0.3721 mL | 0.7442 mL | 1.8606 mL | |
| 30 mM | 0.0620 mL | 0.3101 mL | 0.6202 mL | 1.5505 mL | |
| 40 mM | 0.0465 mL | 0.2326 mL | 0.4652 mL | 1.1629 mL | |
| 50 mM | 0.0372 mL | 0.1861 mL | 0.3721 mL | 0.9303 mL | |
| 60 mM | 0.0310 mL | 0.1551 mL | 0.3101 mL | 0.7753 mL | |
| 80 mM | 0.0233 mL | 0.1163 mL | 0.2326 mL | 0.5814 mL | |
| 100 mM | 0.0186 mL | 0.0930 mL | 0.1861 mL | 0.4652 mL |